~~<i id='85728006A0'><strike id='85728006A0'><tt id='85728006A0'><pre id='85728006A0'></pre></tt></strike></i>~~

Home» explore» hotspot

hotspot

author：leisure time 2025-10-06 11:53:11 Page View：8

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Why doctors need education on FDA device approval process
Next article： Alkermes shareholders re

explore

DIEP, the 'gold standard' of breast reconstruction, is under threat

AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

NEJM study measures Covid brain fog, impact on IQ

AdobeOfallthelingeringsymptomsoflongCovid,difficultyfocusingandthinking,knownasbrainfog,maybethemost

Bright Health sells Medicare Advantage business to Molina

BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

Why doctors need education on FDA device approval process

AdobeInherfinalpresentationforhealthpolicyclassattheUniversityofChicago,first-yearmedicalstudentRobi